Delta-Fly Pharma, Inc.
4598.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.41B
Close$
Share Statistics
| Market cap | $1.41 Billion |
|---|---|
| Enterprise Value | $1.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-140.45 |
| Beta | -0.71 |
| Outstanding Shares | 13,988,813 |
Return
| Return on Equity | 857.90% |
|---|---|
| Return on Assets | -1117.09% |
| Return on Invested Capital | 851.06% |
Valuation & Multiples
| P/E Ratio | -0.73 |
|---|---|
| PEG | -4.81 |
| Price to Sales | - |
| Price to Book Ratio | -6.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.79 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Delta-Fly Pharma, Inc.
12 employees
CEO: Kiyoshi Eshima Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers...